# US 2025/0027116 A1 · Methods for large-size chromosomal transfer and modified chromosomes and organisims using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0027116 A1
- Document ID: US20250027116A1
- Status: Published application
- Kind: A1
- Application number: 18/694,660
- Filed: 2022-09-23
- Published: 2025-01-23
- Earliest claimed: 2021-09-24
- Assignees: Immunocan Biotech Co. Ltd.
- Applicants: Immunocan Biotech Co. Ltd.
- Inventors: Jiwei ZHANG; Yu WEI
- Web page: https://patentgrep.com/patent/US20250027116A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/907: {in mammalian cells}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 5/0603: {Embryonic cells (production of embryos, nuclear transfer A01K67/027); Embryoid bodies}
- C12N 5/166: {resulting from interspecies fusion}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2207/15: Humanized animals
- A01K 2217/072: maintaining or altering function, i.e. knock in
- A01K 2227/105: Murine
- C07K 2317/21: from primates, e.g. man
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 2015/8518: {expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Methods of transferring large sequence fragments between chromosomes and generating chromosomal rearrangements using double strand break repair pathways and homology directed repair. Further relates to chromosomes produced by these methods, and cells and transgenic animals comprising these chromosomes.

## Claims

### Claim 1

A method of generating an engineered chromosome, comprising:
a. providing a cell comprising a target chromosome comprising a target sequence and a template chromosome comprising a template sequence;
b. contacting the cell with
i. a first nucleic acid molecule comprising from 5′ to 3′, a 5′ homology arm comprising a nucleotide sequence upstream of the 5′ end of the target sequence, at least a first marker, and a 3′ homology arm comprising a nucleotide sequence upstream of the 5′ end of the template sequence; and
ii. a second nucleic acid molecule comprising from 5′ to 3′, a 5′ homology arm comprising a nucleotide sequence downstream of the 3′ end of the template sequence, at least a second marker, and a 3′ homology arm comprising a nucleotide sequence downstream of the 3′ end of the target sequence;
c. generating a double strand break at or on both sides of the target sequence, and at the 5′ and 3′ ends of the template sequence, whereby the template sequence and the first and second markers are inserted into the target chromosome; and
d. selecting a cell or cells expressing the first and second markers.

### Claim 2 (depends on 1)

The method of claim 1, wherein the first marker is located at the 5′ end of the template sequence and the second marker is located at the 3′ end of the template sequence following insertion of the template sequence.

### Claim 3 (depends on 1)

The method of claim 1, wherein the 5′ and 3′ homology arms of the first and second nucleic acid molecules are between about 20 and 2,000 bp, between about 50 and 1,500 bp, between about 100 and 1,400 bp, between about 150 and 1,300 bp, between about 200 and 1,200 bp, between about 300 and 1,100 bp, between about 400 and 1,000 bp, or between about 500 and 900 bp, or between about 600 bp and 800 bp in length.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the template sequence is between 50 KB and 250 MB, 50 KB and 100 MB, 50 KB and 50 MB, 50 KB and 20 MB, 50 KB and 10 MB, 50 KB and 5 MB, 50 KB and 3 MB, 50 KB and 2 MB, 50 KB and 1 MB, 100 KB and 200 MB, 100 KB and 100 MB, 100 KB and 50 MB, 100 KB and 20 MB, 100 KB and 10 MB, 100 KB and 5 MB, 100 KB and 3 MB, 100 KB and 2 MB, 100 KB and 1 MB, 100 KB and 500 KB, 200 KB and 100 MB, 200 KB and 50 MB, 200 KB and 20 MB, 200 KB and 10 MB, 200 KB and 5 MB, 200 KB and 3 MB, 200 KB and 2 MB, 200 KB and 1 MB, 200 KB and 500 KB, 500 KB and 100 MB, 500 KB and 50 MB, 500 KB and 20 MB, 500 KB and 10 MB, 500 KB and 5 MB, 500 KB and 3 MB, 500 KB and 2 MB, 500 KB and 1 MB, 1 MB and 100 MB, 1 MB and 50 MB, 1 MB and 20 MB, 1 MB and 10 MB, 1 MB and 5 MB, 1 MB and 3 MB, 1 MB and 2 MB, 3 MB and 100 MB, 3 MB and 50 MB, 3 MB and 20 MB, 3 MB and 10 MB, 3 MB and 5 MB, 5 MB and 100 MB, 5 MB and 50 MB, 5 MB and 20 MB, 5 MB and 10 MB, 10 MB and 100 MB, 10 MB and 50 MB, or 10 MB and 20 MB, in length.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein generating the double strand breaks at (c) comprises using a CRISPR/Cas endonuclease and one or more guide nucleic acids (gNAs), one or more zinc finger nucleases, one or more Transcription Activator-Like Effector Nucleases (TALENs), or one or more CRE recombinase to induce the double strand breaks.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the target chromosome comprises, from 5′ to 3′, the sequence of the 5′ homology arm of the first nucleic acid molecule, the target sequence, and the sequence of 3′ homology arm of the second nucleic acid molecule.

### Claim 15 (depends on 1)

The method of claim 1, wherein the template chromosome comprises, from 5′ to 3′, the sequence of the 3′ homology arm of the first nucleic acid molecule, the template sequence, and the sequence of the 5′ homology arm of the second nucleic acid molecule.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method of claim 1, wherein the target sequence comprises one or more genes that are homologous to one or more genes of the template sequence.

### Claim 18 (depends on 1)

The method of claim 1, wherein the template sequence comprises a naturally occurring sequence.

### Claim 19 (depends on 18)

The method of claim 18, wherein the template sequence comprises one or more modifications to the naturally occurring sequence.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The method of claim 1, wherein the template sequence comprises an artificial sequence.

### Claim 22 (depends on 21)

The method of claim 21, wherein the artificial sequence comprises a sequence encoding one or more antibodies or antigen binding fragments thereof.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein the target sequence is deleted by the insertion of the template sequence.

### Claim 25 (depends on 24)

The method of claim 24, wherein:
a. the target chromosome comprises, from 5′ to 3′, the sequence of the 5′ homology arm of the first nucleic acid molecule, a first sgRNA target sequence, the target sequence, a second sgRNA target sequence, and the sequence of 3′ homology arm of the second nucleic acid molecule; and
b. the template chromosome comprises, from 5′ to 3′, a third sgRNA target sequence, the sequence of the 3′ homology arm of the first nucleic acid molecule, the template sequence, the sequence of the 5′ homology arm of the second nucleic acid molecule, and a fourth sgRNA target sequence.

### Claim 26 (depends on 25)

The method of claim 25, wherein generating the double stranded breaks comprises contacting the cell with a CRISPR/Cas endonuclease, and the first, second, third, and fourth sgRNAs.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The method of claim 1, wherein inserting the template sequence comprises little or no deletion of a sequence of the target sequence.

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32 (depends on 29)

The method of claim 29, wherein
a. the target chromosome comprises, from 5′ to 3′, the sequence of the 5′ homology arm of the first nucleic acid molecule, a first sgRNA target sequence, and the sequence of 3′ homology arm of the second nucleic acid molecule; and
b. the template chromosome comprises, from 5′ to 3′, a second sgRNA target sequence, the sequence of the 3′ homology arm of the first nucleic acid molecule, the template sequence, the sequence of the 5′ homology arm of the second nucleic acid molecule, and a third sgRNA target sequence.

### Claim 33 (depends on 32)

The method of claim 32, wherein generating the double stranded breaks comprises contacting the cell with a CRISPR/Cas endonuclease, and a first, second, and third sgRNA.

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36 (depends on 1)

The method of claim 1, wherein the first or second marker comprises a fluorescent protein operably linked to a promoter capable of expressing the fluorescent protein in the cell.

### Claim 37

(canceled)

### Claim 38

(canceled)

### Claim 39 (depends on 1)

The method of claim 1, wherein the first marker further comprises a selectable marker, and/or the second marker further comprises a selectable marker and/or the second marker further comprises a selectable marker.

### Claim 40

(canceled)

### Claim 41 (depends on 39)

The method of claim 39, wherein the selectable marker is selected from the group consisting of Dihydrofolate reductase (DHFR), Glutamine synthase (GS), Puromycin acetyltransferase, Blasticidin deaminase, Histidinol dehydrogenase, Hygromycin phosphotransferase (hph), Bleomycin resistance gene and Aminoglycoside phosphotransferase (Neomycin resistance).

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44 (depends on 1)

The method of claim 1, further comprising (e) deleting all or a part of the first or second marker after step (d).

### Claim 45

(canceled)

### Claim 46 (depends on 1)

The method of claim 1, wherein the cells comprise hybrid cells, embryonic hybrid stem (EHS) cells or zygotes.

### Claim 47

(canceled)

### Claim 48 (depends on 46)

The method of claim 46, wherein the EHS cells are generated by fusing human embryonic stem cells to embryonic stem cells from a non-human species.

### Claim 49

(canceled)

### Claim 50 (depends on 46)

The method of claim 46, wherein the EHS cells are generated by fusing ES cells from any two different species selected from the group consisting of mouse, rat, rabbit, guinea pig, hamster, sheep, goat, donkey, cow, horse, camel, chicken and monkey.

### Claim 51 (depends on 46)

The method of claim 46, wherein generating the hybrid cells comprises:
a. generating micronucleated human cells; and
b. fusing the micronucleated human cells with a cell from a non-human species, thereby generating a hybrid cell.

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54

(canceled)

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57 (depends on 1)

The method of claim 1, wherein the target chromosome comprises mouse chromosome 12 and the template chromosome comprises human chromosome 14, or wherein the target chromosome comprises mouse chromosome 6 and the template chromosome comprises human chromosome 2.

### Claim 58 (depends on 57)

The method of claim 57, wherein the target sequence comprises a mouse Igh variable region sequence, a mouse Igk variable region sequence, and/or a mouse Igl variable region sequence.

### Claim 59

(canceled)

### Claim 60 (depends on 57)

The method of claim 57, wherein the template sequence comprises a human IGH variable region sequence, a human IGK variable region sequence, and/or a human IGL variable region sequence.

### Claim 61

(canceled)

### Claim 62 (depends on 1)

The method of claim 1, further comprising recovering the engineered chromosome from the cells selected at step (d).

### Claim 63

(canceled)

### Claim 64

(canceled)

### Claim 65 (depends on 1)

An engineered chromosome produced by the methods of claim 1.

### Claim 66

(canceled)

### Claim 67

(canceled)

### Claim 68

(canceled)

### Claim 69 (depends on 65)

A cell comprising the engineered chromosome of claim 65.

### Claim 70

(canceled)

### Claim 71

(canceled)

### Claim 72

(canceled)

### Claim 73

(canceled)

### Claim 74

(canceled)

### Claim 75 (depends on 1)

A method of generating a mouse embryonic stem cell, comprising:
a. fusing micronucleated cells comprising the engineered chromosome produced by the methods of claim 1 to mouse ES cells, wherein:
i. the mouse ES cells comprise a chromosome homologous to the engineered chromosome, the homologous chromosome comprising a first fluorescent protein operably linked to a promoter capable of expressing the fluorescent protein in the ES cells, and
ii. at least a subset of the micronucleated cells comprise the engineered chromosome, and wherein the engineered chromosome comprises a second fluorescent protein different from the first fluorescent protein, the second fluorescent protein operably linked to a promoter capable of expressing the fluorescent protein in the ES cells;
b. selecting ES cells that express both the first and second fluorescent proteins;
c. culturing the ES cells selected in step (c) until the homologous chromosome is lost by at least a subset of the ES cells; and
d. selecting ES cells that express the second fluorescent protein and do not express the first fluorescent protein.

### Claim 76

(canceled)

### Claim 77

(canceled)

### Claim 78

(canceled)

### Claim 79 (depends on 75)

A transgenic mouse, produced from the mouse ES cell produced by the method of claim 75.

### Claim 80

(canceled)

### Claim 81

(canceled)

### Claim 82

(canceled)

### Claim 83

(canceled)

### Claim 84 (depends on 79)

A method of generating an antibody comprising:
a. challenging the transgenic mouse of claim 79 with an antigen, whereby the transgenic mouse generates a plurality of antibodies comprising human V, D, and J segments from the human IGH variable region; and
b. isolating an antibody specific to the antigen.

### Claim at position 85

85-105. (canceled)
